218 related articles for article (PubMed ID: 36738326)
21. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.
Pallenberg ST; Pust MM; Rosenboom I; Hansen G; Wiehlmann L; Dittrich AM; Tümmler B
Microbiol Spectr; 2022 Oct; 10(5):e0145422. PubMed ID: 36154176
[TBL] [Abstract][Full Text] [Related]
22. Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease.
Giallongo A; Parisi GF; Papale M; Manti S; Mulé E; Aloisio D; Terlizzi V; Rotolo N; Leonardi S
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833376
[TBL] [Abstract][Full Text] [Related]
23. Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.
Sadras I; Kerem E; Livnat G; Sarouk I; Breuer O; Reiter J; Gileles-Hillel A; Inbar O; Cohen M; Gamliel A; Stanleigh N; Gunawardena T; Bartlett C; Gonska T; Moraes T; Eckford PDW; Bear CE; Ratjen F; Kerem B; Wilschanski M; Shteinberg M; Cohen-Cymberknoh M
J Cyst Fibros; 2023 Nov; 22(6):1062-1069. PubMed ID: 37331863
[TBL] [Abstract][Full Text] [Related]
24. Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients.
Wright BA; Ketchen NK; Rasmussen LN; Bartels AR; Singh SB
Pediatr Pulmonol; 2022 Mar; 57(3):655-657. PubMed ID: 34859619
[TBL] [Abstract][Full Text] [Related]
25. Triple Therapy for Cystic Fibrosis
Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
[TBL] [Abstract][Full Text] [Related]
26. Effect of Triple Combination CFTR Modulator Therapy on Sleep in Adult Patients with Cystic Fibrosis.
Welsner M; Schulte T; Dietz-Terjung S; Weinreich G; Stehling F; Taube C; Strassburg S; Schoebel C; Sutharsan S
Respiration; 2022; 101(8):766-774. PubMed ID: 35598598
[TBL] [Abstract][Full Text] [Related]
27. Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
Hudson BN; Jacobs HR; Philbrick A; Zhou XA; Simonsen MM; Safirstein JA; Rotolo SM
J Cyst Fibros; 2022 Nov; 21(6):1066-1069. PubMed ID: 36088208
[TBL] [Abstract][Full Text] [Related]
28. CFTR Modulators: Current Status and Evolving Knowledge.
Regard L; Martin C; Da Silva J; Burgel PR
Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
[TBL] [Abstract][Full Text] [Related]
29. CFTR modulator therapy alters plasma sphingolipid profiles in people with cystic fibrosis.
Westhölter D; Schumacher F; Wülfinghoff N; Sutharsan S; Strassburg S; Kleuser B; Horn PA; Reuter S; Gulbins E; Taube C; Welsner M
J Cyst Fibros; 2022 Jul; 21(4):713-720. PubMed ID: 35168870
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review.
Kapouni N; Moustaki M; Douros K; Loukou I
Children (Basel); 2023 Mar; 10(3):. PubMed ID: 36980112
[TBL] [Abstract][Full Text] [Related]
31. Triple Therapy for Cystic Fibrosis (Elexacaftor, Tezacaftor, and Ivacaftor): Desensitization After Skin Rash.
Santos AI; Pacheco J; Cemlyn-Jones J; Gamboa F
Cureus; 2023 Sep; 15(9):e46228. PubMed ID: 37905296
[TBL] [Abstract][Full Text] [Related]
32. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
[TBL] [Abstract][Full Text] [Related]
33. Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor.
Rysgaard UK; Pedersen CL; Jensen JH; Sørensen L; Philipsen LKD; Leo-Hansen C; Olesen HV
J Cyst Fibros; 2022 Sep; 21(5):844-849. PubMed ID: 35667973
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease.
Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351
[TBL] [Abstract][Full Text] [Related]
35. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
36. Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis.
Olivier M; Kavvalou A; Welsner M; Hirtz R; Straßburg S; Sutharsan S; Stehling F; Steindor M
Front Pharmacol; 2023; 14():1176815. PubMed ID: 37229253
[No Abstract] [Full Text] [Related]
37. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
[TBL] [Abstract][Full Text] [Related]
38. Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation.
Roder L; Simonsen M; Fitzpatrick L; He J; Loucks J
J Manag Care Spec Pharm; 2022 Sep; 28(9):989-996. PubMed ID: 36001103
[No Abstract] [Full Text] [Related]
39. Dual and triple modulator therapy for chronic rhinosinusitis in cystic fibrosis patients.
Uyttebroek S; Claeyssens C; Jorissen M; Dupont L; Van Gerven L
Rhinology; 2024 Mar; ():. PubMed ID: 38530204
[TBL] [Abstract][Full Text] [Related]
40. Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis.
DiMango E; Spielman DB; Overdevest J; Keating C; Francis SF; Dansky D; Gudis DA
Int Forum Allergy Rhinol; 2021 Jan; 11(1):75-78. PubMed ID: 32985756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
